CD8A and neoplasm: Researchers have found that ARG1 blockade, in combination with immune checkpoint inhibitors, can restore CD8+ T cell function in PDAC tumors ex vivo, and that anti-hARG1 monoclonal antibodies increase the number of tumor-specific CD8+ T cells in the tumor and enhance the efficacy of immune checkpoint therapy in humanized mice (133).